NCT07741695Not yet recruiting
Targeting IRAK4 in Chronic Lymphocytic Leukemia
Source: ClinicalTrials.gov · Last updated 4 Aug 2026
Brief summary (registry, in English)
Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 29 Jul 2026
- Start date
- Sept 2026
- Primary completion date
- Sept 2027
- Lead sponsor
- IRCCS San Raffaele
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT07741695
What you commit to
- Study type: Observational
- Planned participants: 50
- From Sept 2026 to the primary completion date, Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Participant is unable or unwilling to provide informed consent for participation in the study
Who the study is looking for
- Age ≥18 years
- Diagnosis of CLL
- Participant is willing and able to give informed consent for participation in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.